Sol-Gel Technologies SLGL
NASDAQ SLGL
$70.14 +0.04 (+0.06%)
As of: Sep 4, 2026 · 3:09 PM EDT

Sol-Gel Technologies (SLGL) Non Operating Interest Expenses (2018 - 2026)

Analysis

Sol-Gel Technologies (SLGL) Non Operating Interest Expenses (2018 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Sol-Gel Technologies 194.87 Mn 146.94 Mn - 481,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 481,000.00
Jun 30, 2025 380,000.00
Jun 30, 2024 352,000.00
Jun 30, 2023 557,000.00
Jun 30, 2022 329,000.00
Jun 30, 2021 9,000.00
Jun 30, 2020 481,000.00
Jun 30, 2019 359,000.00
Jun 30, 2018 379,000.00